


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on October 11, 2000.

Scott K. Larsen



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

CASE NO.: DM-7029

BROWN et al.

SERIAL NO.: 09/454,868

GROUP ART UNIT: 1614

FILED: DECEMBER 3, 1999

EXAMINER: UNKNOWN

FOR: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL DISORDERS

Wilmington, Delaware
Dated: October 11, 2000

Asst. Commissioner for Patents and Trademarks
Washington, D.C. 20231

RECEIVED

OCT 18 2000

Sir:

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below.
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

Please charge any deficiency or credit any overpayment to Deposit Account No. 04-1928.

There are no listed references which are not in the English language or do not contain an English language abstract.

Respectfully submitted,

Scott K. Larsen, Ph.D., J.D.
Attorney for Applicants
Registration No. 38,532
Telephone: 302-992-2368

DuPont Pharmaceuticals Company
C/o Legal-Patents
1007 Market Street
Wilmington, DE 19898